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Immune complex formation causes underdetection of p24 antigen in human immunodefi-
ciency virus (HIV) infection. Brieflyboiling diluted plasma releases all complexed antigen, which
can then be measured by some commercial assays. In a retrospective pediatric cohort study, the
specificity of this procedure in 390 uninfected samples was 96.9% after initial testing and 100%
after neutralization. Sensitivity among 125 postnatal infected samples was, at a detection of 2
pg/ml., 96.0% (97% neutralizable) compared with 47.7% for regular antigen (76% neutraliz-
able), 96% for polymerase chain reaction, and 77% for viral culture. The high sensitivity and
specificity of heat-denatured antigen was confirmed by prospectively testing 113 additional sam-
ples. Quantitative analysis of samples from infected infants showed low levelsof p24 antigen in
29% of cord blood sera, a postnatal increase to levels that were during the first 6 months of life
inversely associated with survival, and persistence of antigenemia thereafter independent of clini-
cal status. Prevalence and antigen levels were significantly lower in mothers. The persistent
antigenemia in children indicates that their immune systems cannot restrict HIV expression as
efficiently as those of adults.
Detection ofhuman immunodeficiency virus type 1 (HIV-
1) p24 antigen in early pediatric HIV infection has been of
low sensitivity, due to the presence of usually high-titered
maternal anti-p24 IgG antibodies, which lead to immune
complex formation ofthe antigen [1-4]. Acid dissociation of
immune complexes has resulted in improved antigen detec-
tion in plasma or serum of infected adults and children [5-
11]. However, we recently showed that the acid-mediated
release of small quantities of antigen from immune com-
plexes is inefficient ifantibodies to p24 antigen are present at
very high titers [12]. In contrast, we have found that boiling
diluted serum leads to the quantitative and irreversible re-
lease of immune-complexed HIV-1 p24 that can be readily
measured with commercial assays that recognize heat-dena-
tured antigen (HD-Ag). In a study of 50 sera from Hlv-posi-
tive adults, this procedure was significantly superior to acid
dissociation.
We used this simple system to analyze serum or plasma
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samples of children born to HIV-I-infected mothers.We
assessed the diagnostic sensitivity and specificity of the pro-
cedure in a cohort of well-characterized pediatric samples
and virus expression in children with HIV-1 infection.
Materials and Methods
Patients and samples. Blood samples were from children
born to HIV-I-seropositive mothers. All children were partici-
pants in the prospective Swiss Neonatal HIV Study, which has
been maintaining a national data base since October 1986 [13].
None of the children had received specific antiretroviral treat-
ment. EDTA-anticoagulated blood samples were collected from
infants at birth (cord blood) and at 3- to 6-month intervals there-
after. A maternal serum sample was collected at delivery. An
infant was considered infected if at least one of the following
criteria was satisfied: positive IgG Western blot (WB) (defined
below) after age 15 months, positive polymerase chain reaction
(peR) or viral culture or neutralizable antigen in ~2 different
blood samples, or death from AIDS. The age at which symptoms
were first recognized (CDC P-2) was defined as the age at onset
of symptomatic HIV infection [14]. Children ruled uninfected
included those with complete seroreversion and negativity by all
tests for viral components (see below) and those with ~2 consec-
utive postnatal samples negative by PCR, provided that all other
tests for viral components were also negative.
The retrospective blinded study for HD-Ag included all fro-
zen serum or plasma samples still available from cohort chil-
dren: 690 samples representing 305 (72.3%) of the 422 infants.
Samples were from 362 boys and 328 girls (ratio: 1.10). The
ratio for the cohort was 193 to 229 (0.84). The median age at
which samples were obtained was 11 months (range, 0-95).
Due to the study design, only few postnatal samples of very
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young infants were available, including 5 from the first and 7
from the second month. Samples from children with verified
presence or absence ofHIV infection were of particular interest:
There were 142 (20.6%) samples from 53 infected children. The
mean age represented by these samples was 18 months (range,
0-92 months). A total of 390 samples (56.5%) was from 134
uninfected children (mean age, 12 months; range, 0-95). For
the remaining 157 samples (22.9%), the status of infection was
not resolved and the results are not described.
In addition to the above samples, 113 samples from cohort
children were analyzed by HD-Ag and PCR in a prospective
study conducted since August. 1992. The age range represented
by these samples was 0 to III months (median II).
Antibody tests. All samples were prospectively tested for
HIV-I IgG by WB using strips from Biotech Research Laborato-
ries (Rockville, MD), Bio-Rad Laboratories (Glattbrugg, Swit-
zerland), or Diagnostic Biotechnology (Geneva). Results were
interpreted on the basis of recommendations of the following
organizations: the Centers for Disease Control and Prevention
and the Association of State and Public Health Laboratory
Directors, the Consortium for Retrovirus Serology Standardiza-
tion, the American Red Cross, and the US Food and Drug Ad-
ministration [15]. A sample was ruled WB-positive if it met crite-
ria for positivity of at least three of the organizations.
Tests for viral components. Assays done prospectively in-
cluded antigen tests with undenatured samples (UD-Ag), viral
culture, and PCR. HD-Ag was tested retrospectively or prospec-
tively. All testing was done blinded.
The Abbott HIV AG EIA (Abbott Diagnostics, Wiesbaden-
Delkenheim, Germany) and later the Du Pont (Bad Nauheim,
Germany) HIV-I p24 core profile ELISA were used for UD-Ag
testing of undiluted serum or plasma samples. Since 1990 (i.e.,
in 55% of all samples evaluated for this study), the tests were
done in duplicate. Positive samples were subjected to confirma-
tory neutralization, using the kits and procedures of the respec-
tive manufacturers.
Viral culture was done prospectively on ficoll-purified periph-
eral blood mononuclear cells (PBMC) cocultured with phytohe-
magglutinin-stimulated PBMC from HIV-negative blood donors
[16]. The sole modification in the technique was that cultures
were kept in 15-mL polyallomer tubes (Falcon; Becton Dickin-
son, Basel, Switzerland). Duplicate samples of supernatants
were tested for UD-Ag twice a week. A positive result required
the presence of antigen above the manufacturer's cutoff level in
at least 2 consecutive samples.
For PCR, duplicates of I-,."g samples of DNA extracted from
ficoll-separated PBMC were amplified with primers from the
HIV-I gag and long terminal repeat regions. Amplified material
was analyzed by a liquid hybridization procedure followed by
resolution of the products on a denaturing gel as described [17].
The procedure can detect a single copy of HIV-I DNA. A posi-
tive result required reaction with both primer regions and at
least one in duplicate. DNA extraction and testing ofall samples
was done blindly. The specificity record ofPCR in routine diag-
nostic applications in our laboratory was >99.6% in 1990 (no
false-positivesamong 287 negative control reactions) and 99.2%
in both 1991 and 1992 (4/531 and 6/708 false-positive reac-
tions, respectively). Accordingly, the probability of a false-posi-
tive result (~3 positive reactions/sample) was negligible (.008)3.
In fact, none of 172 negative control samples obtained and
tested in 1992 had a false-positive result.
For HD-Ag testing, patient or control samples were diluted
with 2 vol ofa 0.5%solution of Triton X-IOO. The diluted sam-
ples were boiled for 5 min in 1.5-mL Eppendorftubes on a dry
heat block (DRI-BLOCK DB-2A; Techne, Cambridge, UK)
and assayed in duplicate by the Du Pont HIV-I p24 core profile
ELISA according to the manufacturer's instructions, except that
incubation of serum or plasma samples was for 2 h at room
temperature on a microplate shaker (Vary Shaker; Dynatech,
Glattbrugg, Switzerland). Antigen standards of 3, 6, 12.5, 25,
50, and 100 pg/mL in duplicate and an antigen-negative control
in triplicate were included in all experiments as described [12].
Samples positive in screening, using a previously established cut-
off of 0.020 absorbance units, were subjected to a confirmatory
neutralization assay (Du Pont). The manufacturer's instructions
were followed with the same exceptions as above.
Statistical analysis. Proportions were compared by x2 test
when the total number of samples was ~40. Fisher's exact test
was used for fewer samples. Ninety-five percent confidence in-
tervals (CI) for proportions were read from tables or calculated
for numbers> 100 [18, 19]. Absorbances were analyzed by Stu-
dent's t test. Survival data were analyzed by the Kaplan-Meier
method and log rank test [20]. All P values shown are two-
tailed.
Results
Specificity ofHD-Ag. Among the 390 samples (including
68 cord blood samples) from children ruled uninfected, retro-
spective testing was positive in 12 samples (ofwhich 3 were
from cord blood), corresponding to a diagnostic specificity of
96.9% (95% CI, 94.8%-98.5%) after initial testing. No mate-
rial was available for neutralization in 8 of the 12 samples
initially positive. Four samples with initial readings of0.047,
0.028, 0.028, and 0.027 were negative by neutralization.
Thus, the diagnostic specificity after neutralization of ini-
tially positive samples was 382 of 382 (100%; 95% CI,
99.2%-100%).
Diagnostic sensitivity. To determine the diagnostic sensi-
tivity ofHD-Ag and the other tests for viral components, all
available results from 53 infected children were compared
(table I). When cord blood samples (in which the sensitivity
of HD-Ag was 29%, i.e., higher than by any other method)
were excluded from the analysis, the overall diagnostic sensi-
tivity of retrospective HD-Ag analysis was 96% (90.9%-
98.7%) versus 47.7% (42.9%-52.6%; P < .001) for UD-Ag.
With respect to neutralization, the HD-Ag again compared
favorably with UD-Ag: As many as 73 (97%) of 75 samples
initially positive for HD-Ag were neutralizable, while only
38 (76%) of 50 samples positive by UD-Ag could be neutral-
ized (P < .004). Both samples initially positive by HD-Ag
that could not be neutralized were borderline (2-3 pg/mL).
320 Schupbach et al. JlD 1994; 170 (August)
Table 1. Diagnostic sensitivity of viral parameters in samples from 53 HIV-infected children and
41 seropositive mothers.
Sample source HD-Ag UD-Ag DNA PCR Viral culture
Cord blood 17,5(29) 18, I (6) 7, I (14) 12. I (8)
Children by age (months)
1-2 3. 3 (100) 4.0(0) 3.3(100) 4,4 (100)
3-4 14.13(93) 14,9(64) 5.5(100) 6. 5 (83)
5-6 8, 7 (88) 10, 5 (50) 3.3(100) 4.2(50)
7-12 19,18(95) 22,9(43) 8, 7 (88) II, 8 (73)
>12 81, 79 (98) 103,50 (49) 60.58 (97) 58.45 (78)
Postnatal 125, 120 (96.0) 153.73(47.7) 79, 76 (96.2) 83, 64 (77.1)
Maternal 41.9(22) 41, 2 (4.9) ND ND
NOTE. Data are no. tested. no. positive (%). HD-Ag, heat-denatured antigen; UD-Ag. undenatured antigen;
DNA PCR, polymerase chain reaction for viral DNA; ND. not done.
Remarkably, in contrast to the high prevalence ofHD-Ag
in children, antigenemia in delivering mothers was consider-
ably less frequent: Only 9 of 41 maternal sera were positive
(22%; CI, 10.6%-37.6%: P < .001), and antigen concentra-
tions ranged from 2 to 14 pg/ml., A similar difference was
found with respect to UD-Ag. Thus, infected children were
significantly more frequently antigen-positive than were
their mothers.
PCR for viral DNA, with 96.2% (89.4%-99.2%) positive
postnatal samples, had sensitivity similar to HD-Ag. In addi-
tion, I sample was positive in duplicate with primers from
the long terminal repeat region of the viral genome but nega-
tive for the gag primers and was thus ruled indeterminate
(see Methods). The sensitivity of virus culture was 77.1%
(66.7%-85.3%) in postnatal samples, which was distinctly in-
ferior to that of HD-Ag (P < .005).
In the prospective testing of 113 pediatric samples, 108
(95.6%) had concordant results for both HD-Ag and PCR
(20 positives, 88 negatives). Among the 5 samples with dis-
cordant results, PCR was correctly positive in 2 samples from
infected children aged III and 31 months, respectively; by
HD-Ag, I was just below cutoff and I was negative. Two
PCR-indeterminate and HD-Ag-negative samples from chil-
dren aged 3 and 16 months, respectively, were probably
from uninfected infants, since ~2 additional samples were
negative by both HD-Ag and PCR analysis. The fifth discor-
dant sample, from cord blood, was positive in screening for
HD-Ag, but negative by PCR. No plasma was left for neutral-
ization, and a fresh sample from this child has not been ob-
tained.
Taken together, the data from both the retrospective and
prospective studies demonstrate that the diagnostic sensitivi-
ties of PCR for viral DNA and HD-Ag in pediatric samples
were virtually identical, even when obtained from children
at early ages.
Antigenemia in mother-infant pairs. Five of 17 cord
blood samples from infected infants in the retrospective
study (29%; CI, 10.3%-56.0%) were positive for HD-Ag (ta-
ble 1). For 4 ofthese cases, maternal serum obtained at deliv-
ery was also available for testing. Comparisons of the absor-
bances of these 4 cord blood/maternal blood pairs
(0.187/0.009, 0.113/0.115, 0.039/0.027, and 0.021/0.004)
showed that none of the mothers had sufficiently high con-
centrations of antigen to account for that in the cord blood
and that, therefore, maternal antigenemia could not be the
direct cause of the cord blood antigenemia. Thus, neither
intrapartum transmission ofantigen nor postpartum contami-
nation of the cord blood sample by maternal blood could
account for the antigen detected in the cord blood.
Of 41 samples obtained from mothers at delivery, only 9
(22%) were positive. Low antigen absorbances ranged from
0.020 to 0.115 (corresponding to 2.1-14.2 pg/ml.; mean,
0.037. Follow-up indicated that 4 (44%) of these women's 9
infants were infected: 2 of these had HD-Ag-positive cord
blood. Only 6 (19%)of the 32 infants born to HD-Ag-nega-
tive mothers were infected: the lower rate of transmission,
however, was not significantly different. Two of the 6 infants
were positive for HD-Ag in cord blood while 4 were negative.
In conclusion, 10 (24%)ofthe 41 infants were infected and 4
(40%) were HD-Ag-positive in cord blood. There was no
indication that these 4 had a worse prognosis than those who
were negative. Their mean survival time was 25.8 months
compared with 17.5 months for those who were antigen-
negative: their mean symptom-free time was 12.5 versus
14.3 months. One of the 4 antigen-positive infants died at
age 8 months. The other 3 are alive: I (child with the highest
antigen concentration) without symptoms at age 36 months
and 2 with symptoms at ages 19 and 40 months. Of the 6
antigen-negative infants, 3 died at 7, 10, and 20 months; 2
are alive without symptoms at ages 25 and 34 months, and 1
is alive with symptoms at age 9 months. Figure 1 shows the
postnatal course of antigenemia in 6 of the 10 infected in-
fants for whom follow-up data were available. There was no
indication that infants with cord blood antigenemia had a
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some children but showing considerable fluctuation in
others.
Prognostic relevanceoflevels ofHD-Ag. Levels ofHD-Ag
in cord blood, at ages 1-6 months, and at 7-12 months were
compared with survival time. The levels of HD-Ag in cord
blood or in infants at 7-12 months were of no prognostic
value (data not shown). By contrast, antigen levels in 20
infected infants within 6 months after birth were inversely
associated with survival time (figure 3). Four of 5 infants in
whom an absorbance ~0.900 was measured in this period
died at 5, 7, 10, and 18 months; 1 is alive with symptoms at
age 20 months. By contrast, only 4 (27%) of 15 infants with
absorbance values <0.900 have died (at ages 5, 8, 20, and 26
Figure 2. Age-dependent concentrations of heat-denatured anti-
gen determined by absorbance values in infected children from
whom ~2 samples could be tested. Cutoff (broken bar) corre-
sponds to --2 pg/mL. Absorbances of 0.100 and 1.000 correspond
to --10 and --100 pg/mL, respectively. Values above detection
range ofEIA reader were recorded as 3.000. A, Antigen in depen-
dence of age and clinical status. Figure differentiates between pa-
tients asymptomatic (CDC P-l) at testing, patients who were still
asymptomatic but developed symptoms before next sample was
taken, and symptomatic patients (CDC P-2). B, Individual courses
of antigenemia. Results of all samples from a patient are connected
by line. wlo, without.
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Figure 1. Postnatal follow-up ofinfected infants positive or nega-
tive for heat-denatured antigen (HD-Ag) in cord blood plasma.
Broken line, cutoff of positivity. asyx, asymptomatic; m, months.
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more rapid postnatal increase in antigen concentrations than
those who were negative.
. HD-Ag as a quantitative marker of virus expression.
Individual quantitative results of HD-Ag testing of infected
children, as expressed by absorbance values, are shown in
figure 2. None of these children received antiretroviral treat-
ment. Thus, the measurements represent the natural course
of infection. The levels ofantigen were lowest in cord blood
(mean absorbance = 0.037; i.e., --4 pg/mL). The mean level
rose to a peak of 0.859 (85 pg/ml.) in samples taken during
the first 3 months after birth and was subsequently within a
range of --40-150 pg/mL. Thus, the mean antigen level of
the infants was >20 times higher than that oftheir mothers at
delivery (P = .018).
Figure 2A shows levels of HD-Ag in dependence of time
and the clinical status of 36 infected children who had ~2
samples tested. After exclusion ofcord blood samples, symp-
tomatic children had, with a mean absorbance of0.918, anti-
gen levels roughly twice as high as children without symp-
toms (mean, 0.497; P = .014). The difference was largely
due to a difference in levels found during the first 2 years
(mean, 1.119 vs. 0.407; P = .004). After age 2 years, the
difference was no longer significant. Symptomatic children
>2 years old had antigen concentrations similar to those
without symptoms.
Individual courses ofantigenemia are shown in figure 2B.
In general, a rapid increase in antigen level during the first
few months of life was found. In some instances, a subse-
quent decrease was observed. In others, the antigen values
remained relatively stable or increased further. Typically, the
antigen levels remained above an absorbance of 0.100
(corresponding to --10 pg/rnl.), being relatively stable in
Discussion
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as sensitive as PCR. Detection of HD-Ag was also highly
specific, as demonstrated by successful neutralization in 97%
of positive samples from infected children and by the fact
that the rare cases of.nitially positive results in samples from
children ruled uninfected were negative when subjected to
neutralization.
The finding of positivity for HD-Ag in -- 30% of cord
blood samples from infected infants is in accordance with
results obtained in other studies that used PCR or viral cul-
ture in samples obtained in the first week oflife [1]. These
data suggest that mother-to-infant transmission of HIV-I oc-
curs in at least one-third of cases in utero. In contrast, our
antigen data do not support the observation seen in investi-
gations using DNA PCR that infants in whom infection is
demonstrated at birth have a more rapid clinical course than
those in whom it is detected later [27]. This discrepancy may
relate to the fact that different viral components, which may
not be strictly related to each other with regard to develop-
ment of disease, are recognized by these two tests. Positivity
by DNA PCR indicates that a small fraction ofPBMC (i.e.,
;;::.1-10/1 00,000 cells) is infected. Recent findings in adults
indicate that in the early stage of infection, the virus is pre-
dominantly localized in lymphoid tissues [28, 29]. The pres-
ence, at sufficient concentration for detection by PCR, of
HIV-infected cells in umbilical cord blood might thus repre-
sent a more advanced stage of infection than the presence of
immune-complexed viral antigen, which may originate in
the lymphatic foci of infection.
Our finding that the level of antigen during the first 6
months oflife is ofprognostic significance is of clinical inter-
est (figure 3). Since the number of cases is small, it will be
necessary to confirm this association in larger studies. How-
ever, these data suggest that testing for HD-Ag might be used
for early diagnosis of pediatric HIV infection and identifica-
tion of infants who may benefit from early antiretroviral
treatment. Furthermore, this prognostic association suggests
that events early in the course of infection influence the clin-
ical course of pediatric HIV infection. Whether these events
are due to viral or host factors or both remains to be eluci-
dated.
In contrast, the presence of HD-Ag in cord blood (figure
1) or after 6 months of life did not correlate with prognosis
nor were antigen levels in children>2 years old significantly
associated with the presence of symptoms (figure 2). The
persistent antigenemia found in virtually all children con-
trasted with the low prevalence ofHD-Ag and the low con-
centrations found in mothers at delivery. Adult HIV-1 infec-
tion is characterized by an initial peak of viral replication
early after infection, which is followed by a period during
which little virus or antigen is present in plasma [7, 30, 31].
In our previous study of samples from 50 infected adults
[12], antigen was found in only 7 (35%) of 20 samples that
had high titers of antibody to p24, a condition associated
36
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Figure 3. Prognostic significance of heat-denatured antigen
(HD-Ag) measured during first 6 months oflife. Survival time of20
children is shown in relation to HD-Ag level in Kaplan-Meier analy-
sis. Five children who had ~ I sample with absorbance ~ 0.900
were compared with 15 children whose samples had absorbances
<0.900. Infants with absorbances <0.900 had significantly longer
survival (log rank test: X2 = 7.28. P < .0 I).
months; II remain alive (range. 22-77 months). Statistical
analysis indicated that the survival times of the two groups
differed significantly (P < .0 I).
The World Health Organization estimates that 10 million
children will have been infected with HIV by the year 2000.
Most will be born in economically poor countries [21]. Thus.
recognition and treatment of pediatric HIV infection are of
increasing importance and depend on sensitive yet afford-
able methods.
Recent studies in which acidification was used for immune
complex dissociation demonstrated that testing for antigen
may identify cases of pediatric HIV-I infection within the
first few weeks of life or even at birth [II. 22]. We have now
found a simple single-step procedure for immune complex
dissociation that does not require chemical reagents. Using
this procedure for retrospective and prospective analysis ofa
cohort of pediatric samples. we found that HD-Ag had the
same diagnostic sensitivity as PCR, which is considered the
most sensitive test for HIV [I, 23-26]. Unfortunately, since
few samples taken during the first few weeks of life were
available, we could not adequately assess the efficacy of the
method in the neonatal period. However, on the basis of the
low detection level (2 pg/mL) and the finding that HD-Ag
yielded more positive findings among cord blood samples
from infected children than PCR, even though our PCR pro-
cedure can detect a single copy of HIV-I DNA [17], we pre-
dict that the test, when done in the early weeks oflife, will be
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with an early stage ofinfection and a more favorable progno-
sis [4, 32, 33]. The prevalence and levels of HD-Ag in the
mothers are in accordance with these findings. The fact that
the asymptomatic infants, despite being infected with viruses
carried by their mothers, had continuously detectable anti-
genemia suggests that, unlike that of adults, an infant's im-
mune system is not capable of controlling HIV expression.
This may represent one of the factors responsible for the
more rapid progression of pediatric HIV infection.
In conclusion, HD-Ag is a sensitive, specific, and quantita-
tive marker for HIV-1 in pediatric infection. These proper-
ties, together with other advantages ofEIAs, such as simplic-
ity, assay speed, the possibility of automatization, and
relatively low cost, render testing for HD-Ag an attractive
alternative to the technically demanding and expensive peR
or time-consuming viral cultivation. The systematic use of
HD-Ag in prospective and retrospective studies larger than
ours should contribute to earlier diagnosis, identification of
children with unfavorable prognosis, and to better knowl-
edge ofquantitative viral aspects in the pathogenesis ofpedi-
atric AIDS.
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